

# Giovanni D'Arena

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4219037/publications.pdf>

Version: 2024-02-01

108  
papers

1,981  
citations

304743

22  
h-index

289244

40  
g-index

108  
all docs

108  
docs citations

108  
times ranked

2932  
citing authors

#	ARTICLE	IF	CITATIONS
1	Italian Cytometry Society (GIC) endorsement of consensus recommendations for measurable residual disease in chronic lymphocytic leukemia. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	1.3	1
2	Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics. <i>Hematological Oncology</i> , 2022, 40, 469-474.	1.7	4
3	Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?. <i>Hematological Oncology</i> , 2022, 40, 835-842.	1.7	1
4	Heterogeneity of clinical and radiological findings of COVID-19. <i>Postgraduate Medical Journal</i> , 2021, 97, 268-269.	1.8	4
5	<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.	7.0	23
6	CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 4239.	3.7	1
7	<i>SF3B1</i> -mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. <i>Haematologica</i> , 2021, 106, 3125-3135.	3.5	12
8	SARS-COV2 Infection in Vaccinated Patients: Look for Clinical History and Test Humoral Immunity. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, , 1-3.	0.6	1
9	Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. <i>Leukemia</i> , 2020, 34, 462-477.	7.2	24
10	Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients. <i>Leukemia Research</i> , 2020, 88, 106267.	0.8	4
11	CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance. <i>Frontiers in Oncology</i> , 2020, 10, 584427.	2.8	14
12	Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7605-7614.	2.0	2
13	Parietal skull extramedullary relapse in multiple myeloma. <i>Postgraduate Medical Journal</i> , 2020, 96, 360-360.	1.8	1
14	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	1.4	33
15	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	3.5	15
16	Metabolic Syndrome, Insulin Resistance, Circadian Disruption, Antioxidants and Pancreatic Carcinoma: an Overview. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 23, 73-77.	0.9	19
17	Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. <i>British Journal of Haematology</i> , 2019, 187, e8-e11.	2.5	14
18	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	3.7	16

#	ARTICLE	IF	CITATIONS
19	CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results. <i>Leukemia Research</i> , 2019, 83, 106169.	0.8	8
20	&lt;p&gt;Dissecting the prevention of estrogen-dependent breast carcinogenesis through Nrf2-dependent and independent mechanisms&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4937-4953.	2.0	12
21	Thalidomide-induced psoriasis in a patient with multiple myeloma. <i>Postgraduate Medical Journal</i> , 2019, 95, 171-171.	1.8	2
22	Monoclonal B-cell lymphocytosis and prostate cancer: Incidence and effects of radiotherapy. <i>Journal of Investigative Medicine</i> , 2019, 67, 779-782.	1.6	3
23	Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the Tj ETQq1 1.0.784314 rgBT /Ov	1.0	1
24	Leg Type Primary Cutaneous Diffuse Large B-Cell Lymphoma. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 378-379.	0.6	0
25	Oxidative stress in chronic lymphocytic leukemia: still a matter of debate. <i>Leukemia and Lymphoma</i> , 2019, 60, 867-875.	1.3	11
26	Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party. <i>Blood</i> , 2019, 134, 2931-2931.	1.4	2
27	A CRISPR/Cas9-Generated Murine Model Reveals Cooperation between BCR Signaling and CDKN2A/2B and TP53 Disruption in Richter Syndrome. <i>Blood</i> , 2019, 134, 4278-4278.	1.4	1
28	Pseudomembranous colitis in acute lymphoblastic leukaemia. <i>Postgraduate Medical Journal</i> , 2018, 94, 361-361.	1.8	0
29	CD200 included in a 4â€marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2018, 36, 543-546.	1.7	21
30	Meningeal Involvement in Primary Plasma Cell Leukemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 556-557.	0.6	1
31	Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response. <i>British Journal of Haematology</i> , 2018, 181, 550-552.	2.5	2
32	<i>NOTCH</i> mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018, 182, 597-602.	2.5	22
33	Clinical Pharmacology of<i>Citrus aurantium</i>and<i>Citrus sinensis</i>for the Treatment of Anxiety. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-18.	1.2	53
34	External validation of the accuracy of â€CLLflow scoreâ€™. <i>Journal of Investigative Medicine</i> , 2018, 66, e6-e6.	1.6	4
35	LDH as Predictive Parameter in Treatment-NaÃve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S213.	0.4	0
36	The Effect of Light Exposure at Night (LAN) on Carcinogenesis via Decreased Nocturnal Melatonin Synthesis. <i>Molecules</i> , 2018, 23, 1308.	3.8	25

#	ARTICLE	IF	CITATIONS
37	Mutations in the 3' untranslated region of <i>NOTCH1</i> are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e305-e309.	3.5	18
38	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. <i>Haematologica</i> , 2017, 102, e352-e355.	3.5	9
39	Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2633-2641.	1.3	19
40	Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e443-e446.	3.5	11
41	Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2017, 99, 306-314.	2.2	12
42	Unusual Hypergranular Myelomatous Plasma Cells. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 617-618.	0.6	0
43	Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1424-1432.	1.3	43
44	MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 97-103.	4.4	65
45	Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-13.	2.2	29
46	Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role. <i>Journal of Immunology Research</i> , 2016, 2016, 1-7.	2.2	15
47	Role of Viral miRNAs and Epigenetic Modifications in Epstein-Barr Virus-Associated Gastric Carcinogenesis. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-11.	4.0	26
48	Serum levels of soluble calreticulin predict for time to first treatment in early chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 983-985.	2.5	7
49	Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience. <i>Leukemia and Lymphoma</i> , 2016, 57, 2429-2431.	1.3	10
50	LDH Levels Predict Progression-Free Survival in Treatment-Naïve Patients with Trisomy 12 Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3211-3211.	1.4	2
51	The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. <i>Blood Transfusion</i> , 2016, 14, 255-61.	0.4	21
52	Mutations at 3' Untranslated Region (3'UTR) of NOTCH1 Are Associated with Low CD20 Expression Levels in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 306-306.	1.4	0
53	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. <i>Blood</i> , 2016, 128, 3240-3240.	1.4	0
54	Characterization and Prognostic Relevance of Circulating Microvesicles in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4375-4375.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Lack of Prognostic Significance of the Conventional and Novel Prognostic Markers in Trisomy 12 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 4354-4354.	1.4	0
56	Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study. <i>Blood</i> , 2016, 128, 4494-4494.	1.4	0
57	Comprehensive Characterization of NOTCH1 Mutational Status in Chronic Lymphocytic Leukemia: Clinical Relevance of Subclonal Mutations and Mutation Types. <i>Blood</i> , 2016, 128, 3195-3195.	1.4	0
58	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. <i>Stem Cell Research and Therapy</i> , 2015, 6, 64.	5.5	25
59	Acquired Hemophilia A successfully treated with rituximab. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015024.	1.3	4
60	Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-9.	1.5	44
61	Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells. <i>Leukemia and Lymphoma</i> , 2015, 56, 2458-2459.	1.3	3
62	High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. <i>Tumor Biology</i> , 2015, 36, 9739-9752.	1.8	159
63	Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. <i>Leukemia Research</i> , 2015, 39, 1066-1070.	0.8	29
64	SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. <i>Journal of Clinical Investigation</i> , 2015, 126, 181-194.	8.2	44
65	SLAMF1/CD150 Activates Autophagy in Chronic Lymphocytic Leukemia Cells, Modulating Chemotaxis and Responses to Therapy. <i>Blood</i> , 2015, 126, 1728-1728.	1.4	0
66	More on spontaneous regression of chronic lymphocytic leukemia: two new cases and potential role of lamivudine in a further patient with advanced disease and hepatitis B virus infection. <i>Leukemia and Lymphoma</i> , 2014, 55, 1955-1957.	1.3	0
67	Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498. <i>Expert Opinion on Therapeutic Patents</i> , 2014, 24, 821-828.	5.0	17
68	Alemtuzumab and Treatment of Chronic Lymphocytic Leukemia and Its Immune-Related Disorders: One Player on Two Tables. <i>Acta Haematologica</i> , 2014, 132, 237-239.	1.4	0
69	Fournier's gangrene complicating thrombocytopenia treated with steroids. <i>Lancet</i> , The, 2014, 383, 1580.	13.7	4
70	Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. <i>Leukemia and Lymphoma</i> , 2014, 55, 841-847.	1.3	17
71	Darier sign and cutaneous involvement in mastocytosis. <i>British Journal of Haematology</i> , 2014, 167, 440-440.	2.5	1
72	Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy. <i>OncoTargets and Therapy</i> , 2014, 7, 1043.	2.0	9

#	ARTICLE	IF	CITATIONS
73	HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. <i>Haematologica</i> , 2014, 99, 888-896.	3.5	43
74	NOTCH1 Mutations Are Associated with Low CD20 Expression in Chronic Lymphocytic Leukemia: Evidences for a NOTCH1-Mediated Epigenetic Regulatory Mechanism. <i>Blood</i> , 2014, 124, 296-296.	1.4	5
75	Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience. <i>Blood</i> , 2014, 124, 5655-5655.	1.4	1
76	NOTCH1 Mutated IGHV Unmutated Chronic Lymphocytic Leukemia Cells Are Characterized By a Constitutive Overexpression of Nucleophosmin-1 and Ribosome-Associated Components. <i>Blood</i> , 2014, 124, 3308-3308.	1.4	6
77	Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome. <i>Annals of Hematology</i> , 2013, 93, 1261-2.	1.8	0
78	An Urologic Face of Chronic Lymphocytic Leukemia: Sequential Prostatic and Penis Localization. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013008.	1.3	4
79	No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. <i>Blood</i> , 2013, 121, 1240-1242.	1.4	23
80	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , 2013, 122, 3317-3321.	1.4	48
81	Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	12
82	Fournier's Gangrene Complicating Hematologic Malignancies: Literature Review and Treatment Suggestions. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013067.	1.3	15
83	Abstract 2302: The extracellular form of NAMPT contributes to creating a proinflammatory environment in chronic lymphocytic leukemia.. , 2013, , .		0
84	Functional Effects Of NOTCH1 Mutations In Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2013, 122, 4117-4117.	1.4	0
85	Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study. <i>Blood</i> , 2013, 122, 5309-5309.	1.4	0
86	Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?. <i>American Journal of Blood Research</i> , 2013, 3, 52-7.	0.6	17
87	REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012053.	1.3	12
88	Chronic Lymphocytic Leukemia After Chronic Myeloid Leukemia in the Same Patient: Two Different Genomic Events and a Common Treatment?. <i>Journal of Clinical Oncology</i> , 2012, 30, e327-e330.	1.6	11
89	A shorter time to the first treatment may be predicted by the absolute number of regulatory T cells in patients with Rai stage 0 chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 628-631.	4.1	32
90	Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia. <i>Leukemia and Lymphoma</i> , 2011, 52, 701-704.	1.3	19

#	ARTICLE	IF	CITATIONS
91	Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. <i>Leukemia Research</i> , 2011, 35, 363-368.	0.8	128
92	Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. <i>European Journal of Haematology</i> , 2010, 85, 502-507.	2.2	22
93	Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. <i>European Journal of Haematology</i> , 2009, 82, 235-239.	2.2	22
94	Combined fine needle cytology and flow cytometry immunophenotyping for diagnosis of lymphoid disorders. <i>Leukemia and Lymphoma</i> , 2008, 49, 1212-1213.	1.3	0
95	Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2008, 8, 62-68.	1.2	10
96	DAT-negative hemolytic anemia in a chronic lymphocytic leukemia patient treated with alemtuzumab. <i>Leukemia and Lymphoma</i> , 2007, 48, 625-627.	1.3	3
97	CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. <i>Blood</i> , 2007, 110, 4012-4021.	1.4	149
98	Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1072-1080.	1.3	30
99	Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2007, 82, 787-791.	4.1	39
100	Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. <i>European Journal of Haematology</i> , 2007, 79, 53-58.	2.2	71
101	Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2006, 81, 598-602.	4.1	93
102	Successful Engraftment of Autologous CD34+ Stem Cells after High-Dose Therapy and Fixed Dose (6) Tj ETQq0 0 0,rgBT /Overlock 10 TF	1.4	0
103	Guillain-Barré Syndrome Complicating Mobilization Therapy in a Case of B-cell Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 1489-1490.	1.3	9
104	Quantitative Evaluation of CD52 Expression in B-Cell Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 1255-1257.	1.3	1
105	Improvement of B-Cell Chronic Lymphocytic Leukemia During Haemodialysis: Possible Role for Endogenous Production of Factors Involved in Angiogenesis and Apoptosis?. <i>Leukemia and Lymphoma</i> , 2003, 44, 1263-1265.	1.3	2
106	Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. <i>American Journal of Hematology</i> , 2000, 64, 275-281.	4.1	91
107	Chronic Lymphoproliferative Disorders: An Integrated Point of View for the Differential Diagnosis. <i>Leukemia and Lymphoma</i> , 2000, 36, 225-237.	1.3	20
108	SPONTANEOUS REMISSION IN ACUTE MYELOID LEUKAEMIA: A ROLE FOR ENDOGENOUS PRODUCTION OF TUMOUR NECROSIS FACTOR AND INTERLEUKIN-2?. <i>British Journal of Haematology</i> , 1994, 87, 879-880.	2.5	41